Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of RPT193 in adults with moderate-to-severe T2-high asthma
2022-502854-16-00Phase 2Completed
- Sponsor
- RAPT Therapeutics
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing RPT193 + ICS/LABA with Placebo + ICS/LABA (2 arms). Primary endpoint: Loss of asthma control (LOAC) composite endpoint. Started Oct 2023; status: completed.
02
Drugs
zelnecirnon
03
Conditions
asthma
Beyond the preview
Go deeper on 2022-502854-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502854-16-00.